DENTSPLY SIRONA INC (XRAY) Stock Fundamental Analysis

NASDAQ:XRAY • US24906P1093

12.95 USD
+0.14 (+1.09%)
At close: Feb 13, 2026
12.82 USD
-0.13 (-1%)
After Hours: 2/13/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to XRAY. XRAY was compared to 186 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of XRAY while its profitability can be described as average. XRAY has a valuation in line with the averages, but on the other hand it scores bad on growth. XRAY also has an excellent dividend rating.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • XRAY had positive earnings in the past year.
  • In the past year XRAY had a positive cash flow from operations.
  • In the past 5 years XRAY reported 4 times negative net income.
  • XRAY had a positive operating cash flow in each of the past 5 years.
XRAY Yearly Net Income VS EBIT VS OCF VS FCFXRAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B -1.5B

1.2 Ratios

  • XRAY has a Return On Assets (-15.60%) which is comparable to the rest of the industry.
  • With a Return On Equity value of -59.68%, XRAY perfoms like the industry average, outperforming 47.31% of the companies in the same industry.
  • XRAY's Return On Invested Capital of 5.04% is fine compared to the rest of the industry. XRAY outperforms 76.34% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for XRAY is below the industry average of 8.83%.
  • The 3 year average ROIC (4.11%) for XRAY is below the current ROIC(5.04%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -15.6%
ROE -59.68%
ROIC 5.04%
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
XRAY Yearly ROA, ROE, ROICXRAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40

1.3 Margins

  • With a decent Operating Margin value of 7.48%, XRAY is doing good in the industry, outperforming 74.19% of the companies in the same industry.
  • In the last couple of years the Operating Margin of XRAY has declined.
  • Looking at the Gross Margin, with a value of 51.10%, XRAY is in line with its industry, outperforming 46.77% of the companies in the same industry.
  • In the last couple of years the Gross Margin of XRAY has remained more or less at the same level.
Industry RankSector Rank
OM 7.48%
PM (TTM) N/A
GM 51.1%
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
XRAY Yearly Profit, Operating, Gross MarginsXRAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so XRAY is destroying value.
  • The number of shares outstanding for XRAY has been reduced compared to 1 year ago.
  • The number of shares outstanding for XRAY has been reduced compared to 5 years ago.
  • Compared to 1 year ago, XRAY has a worse debt to assets ratio.
XRAY Yearly Shares OutstandingXRAY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
XRAY Yearly Total Debt VS Total AssetsXRAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

  • XRAY has an Altman-Z score of 0.97. This is a bad value and indicates that XRAY is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of XRAY (0.97) is comparable to the rest of the industry.
  • The Debt to FCF ratio of XRAY is 29.94, which is on the high side as it means it would take XRAY, 29.94 years of fcf income to pay off all of its debts.
  • XRAY's Debt to FCF ratio of 29.94 is fine compared to the rest of the industry. XRAY outperforms 68.28% of its industry peers.
  • A Debt/Equity ratio of 1.36 is on the high side and indicates that XRAY has dependencies on debt financing.
  • XRAY has a Debt to Equity ratio of 1.36. This is in the lower half of the industry: XRAY underperforms 77.42% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.36
Debt/FCF 29.94
Altman-Z 0.97
ROIC/WACC0.57
WACC8.89%
XRAY Yearly LT Debt VS Equity VS FCFXRAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.3 Liquidity

  • A Current Ratio of 1.47 indicates that XRAY should not have too much problems paying its short term obligations.
  • XRAY's Current ratio of 1.47 is on the low side compared to the rest of the industry. XRAY is outperformed by 74.19% of its industry peers.
  • XRAY has a Quick Ratio of 1.47. This is a bad value and indicates that XRAY is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of XRAY (0.99) is worse than 74.19% of its industry peers.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 0.99
XRAY Yearly Current Assets VS Current LiabilitesXRAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for XRAY have decreased strongly by -14.59% in the last year.
  • XRAY shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -7.38% yearly.
  • The Revenue has decreased by -7.08% in the past year.
  • Measured over the past years, XRAY shows a decrease in Revenue. The Revenue has been decreasing by -1.17% on average per year.
EPS 1Y (TTM)-14.59%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%-26%
Revenue 1Y (TTM)-7.08%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.94%

3.2 Future

  • The Earnings Per Share is expected to grow by 7.40% on average over the next years.
  • XRAY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.34% yearly.
EPS Next Y-2.05%
EPS Next 2Y-3.44%
EPS Next 3Y1.79%
EPS Next 5Y7.4%
Revenue Next Year-4.27%
Revenue Next 2Y-1.83%
Revenue Next 3Y-0.41%
Revenue Next 5Y1.34%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
XRAY Yearly Revenue VS EstimatesXRAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B 4B
XRAY Yearly EPS VS EstimatesXRAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0.5 1 1.5 2 2.5

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 8.20, the valuation of XRAY can be described as very reasonable.
  • 96.77% of the companies in the same industry are more expensive than XRAY, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 27.97. XRAY is valued rather cheaply when compared to this.
  • With a Price/Forward Earnings ratio of 8.32, the valuation of XRAY can be described as very reasonable.
  • XRAY's Price/Forward Earnings ratio is rather cheap when compared to the industry. XRAY is cheaper than 97.31% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.96, XRAY is valued rather cheaply.
Industry RankSector Rank
PE 8.2
Fwd PE 8.32
XRAY Price Earnings VS Forward Price EarningsXRAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of XRAY indicates a rather cheap valuation: XRAY is cheaper than 96.77% of the companies listed in the same industry.
  • XRAY's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. XRAY is cheaper than 78.49% of the companies in the same industry.
Industry RankSector Rank
P/FCF 32.3
EV/EBITDA 7.42
XRAY Per share dataXRAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.44%
EPS Next 3Y1.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

7

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 5.17%, XRAY is a good candidate for dividend investing.
  • XRAY's Dividend Yield is rather good when compared to the industry average which is at 0.20. XRAY pays more dividend than 99.46% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.79, XRAY pays a better dividend.
Industry RankSector Rank
Dividend Yield 5.17%

5.2 History

  • The dividend of XRAY is nicely growing with an annual growth rate of 11.21%!
  • XRAY has been paying a dividend for at least 10 years, so it has a reliable track record.
  • XRAY has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)11.21%
Div Incr Years6
Div Non Decr Years30
XRAY Yearly Dividends per shareXRAY Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6

5.3 Sustainability

  • XRAY has negative earnings and hence a negative payout ratio. The dividend may be in danger.
  • XRAY's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP-14.4%
EPS Next 2Y-3.44%
EPS Next 3Y1.79%
XRAY Yearly Income VS Free CF VS DividendXRAY Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B -1.5B

More info and screens

Find the best dividend stocksShow peers with best dividend

DENTSPLY SIRONA INC

NASDAQ:XRAY (2/13/2026, 8:00:02 PM)

After market: 12.82 -0.13 (-1%)

12.95

+0.14 (+1.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06
Earnings (Next)02-26
Inst Owners107.4%
Inst Owner Change-0.9%
Ins Owners0.24%
Ins Owner Change-1.58%
Market Cap2.58B
Revenue(TTM)3.62B
Net Income(TTM)-882.00M
Analysts68.18
Price Target13.01 (0.46%)
Short Float %7.41%
Short Ratio3.92
Dividend
Industry RankSector Rank
Dividend Yield 5.17%
Yearly Dividend0.62
Dividend Growth(5Y)11.21%
DP-14.4%
Div Incr Years6
Div Non Decr Years30
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.77%
Min EPS beat(2)-19.03%
Max EPS beat(2)1.49%
EPS beat(4)2
Avg EPS beat(4)-3.17%
Min EPS beat(4)-40.52%
Max EPS beat(4)45.37%
EPS beat(8)3
Avg EPS beat(8)-1.68%
EPS beat(12)6
Avg EPS beat(12)4.59%
EPS beat(16)7
Avg EPS beat(16)1.99%
Revenue beat(2)0
Avg Revenue beat(2)-1.42%
Min Revenue beat(2)-1.67%
Max Revenue beat(2)-1.16%
Revenue beat(4)1
Avg Revenue beat(4)-1.42%
Min Revenue beat(4)-3.62%
Max Revenue beat(4)0.77%
Revenue beat(8)2
Avg Revenue beat(8)-1.44%
Revenue beat(12)5
Avg Revenue beat(12)-0.9%
Revenue beat(16)5
Avg Revenue beat(16)-2.02%
PT rev (1m)1.71%
PT rev (3m)-19.68%
EPS NQ rev (1m)0.15%
EPS NQ rev (3m)-15.22%
EPS NY rev (1m)0.02%
EPS NY rev (3m)-14.61%
Revenue NQ rev (1m)0.1%
Revenue NQ rev (3m)-0.28%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)-0.21%
Valuation
Industry RankSector Rank
PE 8.2
Fwd PE 8.32
P/S 0.71
P/FCF 32.3
P/OCF 11.69
P/B 1.75
P/tB N/A
EV/EBITDA 7.42
EPS(TTM)1.58
EY12.2%
EPS(NY)1.56
Fwd EY12.02%
FCF(TTM)0.4
FCFY3.1%
OCF(TTM)1.11
OCFY8.55%
SpS18.16
BVpS7.41
TBVpS-4.29
PEG (NY)N/A
PEG (5Y)N/A
Graham Number16.23
Profitability
Industry RankSector Rank
ROA -15.6%
ROE -59.68%
ROCE 6.38%
ROIC 5.04%
ROICexc 5.51%
ROICexgc 13.81%
OM 7.48%
PM (TTM) N/A
GM 51.1%
FCFM 2.21%
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
ROICexc(3y)4.36%
ROICexc(5y)4.5%
ROICexgc(3y)15.64%
ROICexgc(5y)20.94%
ROCE(3y)5.38%
ROCE(5y)5.49%
ROICexgc growth 3Y-31.16%
ROICexgc growth 5Y-12.42%
ROICexc growth 3Y-13.44%
ROICexc growth 5Y-4.44%
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
F-Score4
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 1.36
Debt/FCF 29.94
Debt/EBITDA 3.26
Cap/Depr 40.63%
Cap/Sales 3.89%
Interest Coverage 250
Cash Conversion 35.76%
Profit Quality N/A
Current Ratio 1.47
Quick Ratio 0.99
Altman-Z 0.97
F-Score4
WACC8.89%
ROIC/WACC0.57
Cap/Depr(3y)46.81%
Cap/Depr(5y)41.51%
Cap/Sales(3y)4.1%
Cap/Sales(5y)3.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.59%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%-26%
EPS Next Y-2.05%
EPS Next 2Y-3.44%
EPS Next 3Y1.79%
EPS Next 5Y7.4%
Revenue 1Y (TTM)-7.08%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.94%
Revenue Next Year-4.27%
Revenue Next 2Y-1.83%
Revenue Next 3Y-0.41%
Revenue Next 5Y1.34%
EBIT growth 1Y3.04%
EBIT growth 3Y-28.45%
EBIT growth 5Y-13.75%
EBIT Next Year42.48%
EBIT Next 3Y13.79%
EBIT Next 5Y11.96%
FCF growth 1Y-63.3%
FCF growth 3Y-18.29%
FCF growth 5Y-11.45%
OCF growth 1Y-38.44%
OCF growth 3Y-11.14%
OCF growth 5Y-6.32%

DENTSPLY SIRONA INC / XRAY FAQ

What is the ChartMill fundamental rating of DENTSPLY SIRONA INC (XRAY) stock?

ChartMill assigns a fundamental rating of 4 / 10 to XRAY.


What is the valuation status for XRAY stock?

ChartMill assigns a valuation rating of 6 / 10 to DENTSPLY SIRONA INC (XRAY). This can be considered as Fairly Valued.


How profitable is DENTSPLY SIRONA INC (XRAY) stock?

DENTSPLY SIRONA INC (XRAY) has a profitability rating of 4 / 10.


Can you provide the PE and PB ratios for XRAY stock?

The Price/Earnings (PE) ratio for DENTSPLY SIRONA INC (XRAY) is 8.2 and the Price/Book (PB) ratio is 1.75.


Can you provide the dividend sustainability for XRAY stock?

The dividend rating of DENTSPLY SIRONA INC (XRAY) is 7 / 10 and the dividend payout ratio is -14.4%.